Primo Biotechnology

Focus: Primo Biotechnology is a Taiwan-based radiopharmaceutical company focused on oncology imaging and therapy in neurology and cancer indications. The company operates at pre-revenue stage with early-stage pipeline programs.

Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Primo Biotechnology

AI assessmentNot Hiring

No open roles listed right now. Follow Primo Biotechnology to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

18F-PSMA-1007

Prostate Cancer

N/A

Clinical Trials (1)

NCT05422105Diagnostic Performance of 18F-PSMA-1007 PET/CT in Suspected Prostate Cancer Patient

N/A

Help build intelligence for Primo Biotechnology

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity in radiopharmaceuticals, a niche high-growth segment with limited competition and significant unmet need in oncology imaging
Early-stage company allows hands-on involvement in drug development from preclinical through early clinical stages
Focused pipeline in prostate cancer and liver metastasis targeting suggests clear therapeutic strategy with potential for differentiation

Watch Out For

Zero current job openings and no disclosed employee count suggest minimal hiring and possible resource constraints for career growth
Pre-revenue, early-stage status with no disclosed funding or financial data creates uncertainty about runway, burn rate, and long-term viability
Only 2 total clinical trials (1 Phase 1) indicates very early pipeline maturity with extended timeline to meaningful clinical validation

Generated by Claude from Primo Biotechnology's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

18-PSMA

Liver Metastasis Colon Cancer

Phase 1

Clinical Trials (1)

NCT06935149Detecting Colorectal Cancer With Liver Metastatic Lesions Using Novel Precise Imaging Tools

Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 2 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

2 pipeline

Marketed

Pipeline